

A Clinicopathological study of Wilms' tumor among Sudanese patients

Hoda M. A. Salih¹, Salwa O. Mekki², Mohamed Elkhatib³, Hani B. Abdelgalil⁴,
Abdelbasit E. Ali⁵, Mohamed A. Salih⁶, Mohammad Shahid Iqbal⁷, Aisha
Tabassum⁸

Author Affiliations:

1. Department of Pathology Alneelain University, Faculty of Medicine, Histopathology Department, Khartoum Radioisotope center (RICK), Khartoum, Sudan.
2. Department of Pathology, Alneelain University, Faculty of Medicine, Histopathology Department Soba University Hospital, Khartoum, Sudan.
3. Department of Pediatrics, Faculty of Medicine, University of Khartoum, Radio Isotope Center, Pediatric Oncology Department, Khartoum-Sudan.
4. Department of Urology, Faculty of Medicine, Alneelain University, Khartoum Sudan.
5. Department of Surgery, Faculty of Medicine, University of Khartoum, Pediatric Surgery. Soba University Hospital, Khartoum Sudan.
6. Prof. Mohamed A Salih passed away on 10th Oct 2013.
7. Department of Pathology, College of Applied Medical Sciences, Umm al Qura University, Makkah, Saudi Arabia.
8. Department of Pathology, College of Applied Medical Sciences, Umm al Qura University, Makkah, Saudi Arabia.

Corresponding Author:

Mohammad Shahid Iqbal, Assistant Professor, Department of Pathology, College of Applied Medical Sciences, Umm al Qura University, Makkah, Saudi Arabia.

Email: mmiqbal@uqu.edu.sa

Abstract

Background: Wilms' tumour is the commonest renal tumour in children, with unique pathogenesis and histology. **Objectives:** To determine the different tumour patterns and components, geographical distribution of the patient's tribes, and the relation of histopathology of the tumour to its clinical presentation and stage. **Materials and Methods:** We collected the data of 51 Wilms' tumor patients from January 2006 to December 2010 inclusive from Soba University Hospital, Radio Isotopes Centre Khartoum (RICK) and the National Health Laboratory (NHL) in Khartoum, Sudan. The data was collected from patient's files using a predesigned questionnaire. Formalin-fixed, paraffin-embedded blocks of processed histopathology specimens were

recut, stained and reviewed. SPSS and Microsoft Office Suite 2010 were used in data analysis. Results: The patients' ages ranged from 0.5 to 10 years with the mean age 3.4 years (SD = 2.1). The male-to-female ratio was 1.6:1.0. Forty two percent of patients were from Western Sudan (n=21). Abdominal mass was the presenting symptom in 50 patients. Duration of symptoms ranged from 3 days to 2 years. Eleven patients (21.6%) presented with metastasis, showing a statistically significant relationship with capsular invasion (P<0.03). Stage III, II, IV and I were diagnosed in 22, 17, 11 and 1 patient, respectively. Triphasic tumours were found in 82.2% of patients, with 61.9% showing mixed elements. Mesenchymal predominance was found in smaller tumours and blastemal predominance in larger tumours (P<0.44). The presence of muscle tissue in the stroma was found to correlate with less advanced stages of the disease (P<0.01). Anaplasia was related to age group 2-6 years (P<0.03), locally infiltrative tumour (P<0.05), and capsular invasion (P<0.02). We found that our results were comparable to other studies conducted in the same region and there is a significant relationship between the histology of the tumour, its size and clinical symptoms.

Key words:

Wilms' Tumor, Nephroblastoma, Anaplasia, Triphasic, Blastema

Introduction:

Wilms' tumour or "nephroblastoma" is one of the most common solid extracranial malignancy in children (1 in 10,000 children, age 0-15 years) and is the commonest paediatric renal tumour [1]. It is a heterologous tumour with unique pathogenesis and histology as it can be tri, bi or mono phasic with different composition of its constituting elements. It is primarily seen in infants with 50% of cases occurring before the age of 3 years, 90% before the age of 6 years, rarely in adults and can be congenital. Some studies show a slight female predominance. The incidence is highest among Africans followed by European and Asian populations. [1]

The incidence rates of Wilms tumor worldwide are not uniform and there is great variation in the incidence between developed and the developing countries (Table 1). Children residing in sub-saharan Africa experience high incidence and a dismal outcome. Tumors in this region harbor wild type mutations and show biologically more aggressive disease [2]. Clues to the origin of Wilms tumor are more likely to come from genetic as opposed to environmental epidemiology. [3,4]

High Income		Upper middle income		Lower middle income		Low income	
Country	Incidence	Country	Incidence	Country	Incidence	Country	Incidence
USA	9.1	Libya	3.3	Egypt	6	Kenya	9.1

Germany	9.7	South Africa	6.1	Iran	3.5	Mali	21.2
Japan	3.5	Turkey	5.4	Algeria	7.9	India	4.4
Malta	13.9	Botswana	4.3	Tunisia	7.6	Uganda	10.5

As the pathogenesis of Wilms' tumor relies mainly on genetics, its' clear ethnic variation is understandable. Literature studying different ethnic groups stated that U.S. blacks and Africans from Ibadan Nigeria had the highest incidence.[6] Before the segregation of the Sudan, when the data for this study was collected, ethnic diversity was at its maximum. Sudan was and still is an ethnic melting pot with variation of races greater than most countries.

Like most cancers, Wilms tumor is characterized by alterations in genes that regulate cell growth, differentiation, and proliferative potential; however, its genetics are more complex than the original Knudson & Strong's two hit theory.[7,8] Its biology illustrates several important aspects of childhood neoplasms: the relationship between malformations and neoplasia, the histologic similarities between organogenesis and oncogenesis, and the role of premalignant lesions.[9] It was found to occur in three settings: sporadically, in association with genetic syndromes, or familial. The sporadic cases form the majority of patients, [10] 10% only are associated with specific medical syndromes, and familial disease is rare. [9]

Several gene mutations are associated with the pathogenesis of Wilms' tumor. The most important is WT1 which is located at chromosome 11p13. Mutations in only 1 allele is enough to promote changes that may lead to the formation of nephroblastoma. [10] Other genes implicated are WT2 (11p15), β -catenin signaling pathway, FWT1 and FWT2 and others[7] Associated syndromes are WAGR, Denys- Drash Syndrome and Beckwith-Weidemann syndrome. The association of Wilms' tumor, aniridia, genitourinary anomalies, and mental retardation has led to the acronym WAGR syndrome.[11,12] Denys-Drash syndrome (DDS), which is a combination of intersex disorder and renal nephropathy, is an extremely rare association of Wilms' tumor.[13] The Beckwith-Weidemann syndrome (BWS) is characterized by umbilical hernia, macroglossia, neonatal hypoglycemia, gigantism, and increased risk for development of certain childhood cancers.[14]

Wilms tumor is one of the success stories of pediatric oncology with long term survival approaching 90% in localized disease and over 70% for metastatic disease. [15,16] There are different treatment schedules adopted by two large cooperative study groups, the National Wilms' Tumor Study Group (NWTSG) and the International Society of Pediatric Oncology (SIOP). Their recommendations differ on the timing of surgery with regards to preoperative chemotherapy. The protocols are a forthright, surgery-based system developed by NWTSG and a delayed surgery-based system developed by the

SIOP.[15] Never the less, radical nephrectomy is the standard of care for these patients with resectable tumors.[17] Prognosis depends mainly on the tumor stage at diagnosis, patient age and histological features (favorable vs. unfavorable depending on presence of diffuse anaplasia).[18] Anaplasia, which is threefold nuclear enlargement, hyperchromasia, and atypical mitotic figures, is the most valued histological prognostic parameter in all the literature.[19]

Cancer in children is an important cause of pediatric morbidity and mortality in Sudan. [20] Limited studies about nephroblastoma in Sudan are available. This study was conducted to investigate the clinical presentation of Wilms' tumor among Sudanese children, its' different geographical distribution, histopathological patterns and their relation to clinical presentation. It was done in the hope of understanding the disease for better management and outcome of the patients. It also reviews the findings of similar work in the region and around the world.

Materials and Methods

This is a descriptive case series based study, carried out in Soba Teaching Hospital, the National Health Laboratory (NHL) and the Pediatric Oncology Department at the Radio Isotope Center Khartoum (RICK).The study sample is comprised of pediatric patients diagnosed with Wilms' tumor in the study area during the period from January, 2006 to December, 2010 inclusive (n=51). Only pediatric cases diagnosed as Wilms' tumor with complete histopathology material are included in this study. Patients with incomplete histopathology material and those older than 16 years old were excluded from this study. Demographic and clinical data was collected from patient records in the laboratory, patient's files at pediatric surgery department archives and the main archive at Soba University Hospital (SUH). Patients who had their surgery in SUH and histopathology analysis at NHL were also included. Patient records at the pediatric oncology archives at RICK were reviewed for more clinical data including information regarding chemotherapy and geographical distribution of the patients' tribes. Patients with valid phone numbers were contacted for some of the missing data in the records.

Formalin-fixed, paraffin-embedded blocks of all processed histopathology specimens were recut and stained with hematoxylin and eosin for review. The information was collected into a predesigned questionnaire. The detailed personal, clinical and pathological data was analyzed using Statistical Package for Social Science Software (SPSS 15, IBM Corporation, Armonk, New York, USA) and Microsoft Office Suite 2010 (Microsoft Corporation, Redmond, Washington, USA). A p value <0.05 was considered significant in Pearson's chi-square (χ^2) test.

Staging and histopathological classification was done as per the National Wilms Tumor Study Group (NWTSG).

Photomicrographs were taken using Olympus BX 51 microscope and attached camera and software at histopathology lab,SUH.

Permission for access of patients' files and histopathology material was obtained from SUH, NHL and RICK administrations respectively. Confidentiality of patients' personal information and clinical data was strictly maintained and handled with utmost discretion.

Results

The study included 51 patients who were diagnosed as Wilms' tumor in a five-year period from January 2006 to December 2010: (Figure 1)




Figure 1: Distribution of Patients among the five year interval of the study.

The age ranged from 0.5 years to 10 years, with the mean age of 3.4 years (SD ± 2.1) (Table. 2).

Age (years)	Right kidney	Left kidney	Unknown	Total
0-2	9	10	0	19
3-6	18	8	0	26
>6	3	2	1	6
Total	30	20	1	51

Age group 3-6 years displayed a statistical significance of right kidney involvement by the tumor (P<0.42). Most patients were males, with male-to-female ratio of 1.55:1. Preoperative chemotherapy was not received by any of the patients. Patients' tribes coming from Western Sudan were 21 patients, 18 patients from tribes of Central Sudan, 7 patients from tribes of Northern Sudan. Only 4 patients came from Southern Sudanese tribes "now the Republic of South Sudan". In one patient the tribe was unknown. The Southern tribes showed a statistical correlation with inoperable tumor (P<0.016) but not with metastasis; however, lung metastasis was strongly related to patients from Western tribes (P<0.024) (figure 2 and table 3).




Figure 2: Map of Sudan showing the geographical distribution of patients' tribes who were diagnosed with Wilm's tumor (2006-2010) as a percentage. (Map 'Not to Scale')

Table 3: Region-wise and Stage-wise distribution of tumors.

		CENTRAL	NORTH	WEST	SOUTH	UNKNOWN	Total
STAGE	I	1	0	0	0	0	1
	II	5	3	8	1	0	17
	III	10	3	9	0	0	22
	IV	2	1	4	3	1	11
Total		18	7	21	4	1	51

Abdominal mass was the commonest presenting symptom seen in 50 patients (98%) and the major cause for seeking medical treatment or consultation. Only one patient sought medical advice due to epistaxis and coincidentally was found to have an abdominal swelling during routine clinical examination. Other presenting symptoms were loss of appetite, weightloss, fever, pain, hematuria and epistaxis (Table 4).

Table 4: Stage-wise clinical presentation									
		ABDOMI NAL MASS	PAIN	HEMATU RIA	FEVE R	WEIG HT LOSS	EPIS TAX IS	OTHER ANOMAL IES	Tot al
STA GE	I	1	0	1	0	1	0	0	3
	II	16	4	2	7	5	1	2	37
	III	22	6	1	6	10	1	2	48
	IV	11	2	1	5	6	0	1	26
Total		50	12	5	18	22	2	5	114

Table 5: Region-wise cases and their clinical presentation									
		Abdomin almass	Pain	Hemat u-ria	Feve r	Weight loss	Epistax is	Other anomalie s	Total
Regio n	Central	18	5	1	6	7	0	1	38
	North	6	3	2	2	4	0	2	19
	West	21	3	2	7	10	2	2	47
	South	4	1	0	2	1	0	0	8
	Unknow n	1	0	0	1	0	0	0	2
Total		50	12	5	18	22	2	5	114

Epistaxis was statistically correlated with an earlier presentation ($P < 0.011$). Hematuria is significantly correlated with smaller mass sizes ($P < 0.040$) and an earlier stage of the disease ($P < 0.019$).

The right kidney was involved by the tumor in 30 patients (58.8%), and the left kidney was involved in 20 patients (39.2%). In one case the involved kidney was not stated in the records. None of the patients were found to have bilateral involvement of the kidneys. Symptoms duration ranged from 3 days to 2 years, commonly 2 months, accounting for 25.5% of patients.

Congenital anomalies were found in 5 patients (9.8%), bilateral undescended testis in 3 (one had congenital glaucoma), back deformity in one and delayed speech in one patient. None of the patients had congenital syndrome (WAGR, Beckwith-Weidemann, or Denys-Drash syndromes). Absence of lymph node metastasis in patients with congenital anomalies showed a statistical significance ($P < 0.045$).

Tumor size measured by radiology ranged from 7 to 23 cm in their greatest diameter. The mean size was 14 cm. Metastasis at presentation was found in 13 patients (21.6%): lung and liver metastasis in 5 patients (9.8%) respectively and adrenal, peritoneum and bone

involvement in 1 patient each (1.96%). Patients with liver and bone metastasis took a longer time to seek medical help. The site of metastasis was significantly correlated with the duration of symptoms ($P < 0.010$). Distant metastasis at presentation was also correlated with capsular invasion ($P < 0.027$).

According to the NWTS staging system, 22 patients (43.14 %) presented at stage III, 17 (33.33%) at stage II, 11 at stage IV (21.57%), and one patient (1.96%) at stage I. Information regarding neoadjuvant therapy was available in two thirds of the patients.

Type of specimens were 37 nephrectomies and 14 biopsies. Preoperative chemotherapy was not given to any of the patients. Triphasic tumors were found in 42 patients (82.2 %), out of which 12 had blastemal predominance and 2 had epithelial and mesenchymal predominance. The size of the mass is correlated to the type of histological predominance in triphasic tumors; Mesenchymal predominance was found in smaller tumors and blastemal predominance was found in larger tumors. Fever is statistically correlated to triphasic tumors with mixed elements ($P < 0.038$). Spindle cell stroma was found in the majority of cases (96.1%). Other components were muscle in 13 cases (25.5%), adipose tissue in 8 cases (15.7%), and squamous or mucinous epithelium in 4 cases (7.8%). Cartilage, bone, neurogenic tissue, and rhabdomyosarcomatouselements had not been detected in any of the cases in this study (Table 6). The presence of muscle in the stroma was found to be correlated with less advanced stages of the disease ($P < 0.016$), and with the absence of weight loss in the presenting symptoms ($P < 0.019$). The presence of adipose tissue was correlated to tumors that were not confined to the kidney ($P < 0.008$). Anaplasia was found in 4 patients in the study group, accounting for 7.8%. It was statistically significant with older age groups ($P < 0.030$), tumor not confined to the kidney ($P < .050$) and presence of capsular invasion ($P < 0.021$). Although all anaplastic tumors were stage III, there was no statistically significant correlation. Capsular invasion was detected in 11 patients (29.7%) . Short duration of symptoms correlated to the absence of capsular invasion ($P < 0.001$). All the tables from table 7 to table 18 shows the various case related data in our study. Out of the 37 nephrectomies, lympho-vascular/renal sinus invasion was detected in 10 patients and only 5 had lymph node metastasis (13.5%). Lymph node metastasis was found to be closely related to capsular invasion ($P < 0.047$). Necrosis was evident in 42 cases (82.4%), 5 of which displayed massive post chemotherapy necrosis (9.8%). The inoperable tumors showed no necrosis in their histology ($P < 0.002$). (Figures 3,4,5and 6).

Table 6: Histological features in different stages of Wilms tumors

Table 6: Histological features in different stages of Wilms tumors						
		I	II	III	IV	Total
Histology	ANAPLASIA	0	0	4	0	4
	SPINDLE	1	17	20	11	49

MUSCLE	0	9	3	1	13
SQUAMOUS/MUCINOUS EPITHELIUM	0	2	2	0	4
ADIPOSE TISSUE	0	2	4	2	8
CASULAR INVASION	0	2	7	2	11
NECROSIS	0	14	19	9	42
EXTENSIVE NECROSIS	0	3	1	1	5
LYMPHOVASCULAR INVASION	0	3	4	3	10

Table 7: Predominant component				
Component	Blastemal	Epithelial	Mesenchymal	Mixed
Number of cases	12	2	2	26




Figure 3: Wilms' tumor with blastemal cells that show anaplasia "large hyperchromatic nuclei with bizarre




Figure 4: Wilms' tumor showing the classical triphasic pattern of blastemal cells, aborted tubules and spindle cell stroma




Figure 5: Wilms' tumor showing blastemal cells and stroma composed of spindle cells, muscle fibers and clusters of adipocytes.




Figure 6: Wilms' tumor showing infiltration of a blood vessel with blastemal cells

STAGE	Tumor confirmed to kidney		Attached to adjacent structures		Anaplasia	
	Yes	No	Yes	No	Yes	No
I	1	0	0	1	0	1
II	14	2	2	14	0	17
III	5	10	11	4	4	18
IV	0	5	5	0	0	11

	Anaplasia		Necrosis	
	Present	Absent	Present	Absent
Tumor confined to kidney	0	20	15	5
Tumor extending beyond kidney	4	14	17	0

Capsular invasion	Lymphovascular invasion		Distant metastasis	
	Yes	No	Yes	No
Present	6	5	2	9
Absent	4	21	2	23
Unknown	0	1	1	0

Anaplasia	Capsular invasion	
	Yes	No
Yes	3	0
No	8	25

Discussion

A significant increase of cancer incidence in Sudan has been witnessed in the last decade. [20] The exact incidence of Wilms’ tumor in Sudan is unknown. That is attributed to the quality of cancer registry and hospital records. The poor registration of medical data was one of the biggest obstacles for this study.

In the 5 year (2006-2010) of this study, 5 children were diagnosed in 2006 and 19 children in 2010. This is almost four-fold increase in the number of diagnosed cases and can partially be explained by the urbanization of the Sudanese population and the expanded workload this has inflicted on Soba University Hospital. The advances in radiographic imaging, histopathology and referral policies may have also contributed to this increase in number.

The mean age at presentation in this study is 3.4 years, maximum age 10 years and minimum age 0.5 years. This correlates well with a similar study in Alexandria Egypt in a 20 year retrospective study, where they found the age of patients ranging between 0.3 and 11.8 years with a mean of 3.5years.[21] Also in a study by Breslow et al (2006) of 7,455 patients, from the National Wilms' Tumor Studies 3,4 and 5, the mean ages for males and females were 3.5 ± 2.8 years and 4 ± 2.9 years, respectively.[22] However, they found strong association between age and gender and none was found in this study, probably due to the smaller study sample size. In a study from Tehran Iran, the median age was found to be 3.16 years, slightly lower than our findings. [22]

The male-to-female ratio in this study is 1.55:1 agreeing with the male predominance found in the studies from Tehran and Alexandria (1.2:1).[21,22] On the other hand NWTS and SIOP studies show a slight female predominance with a male-to-female ratio of 0.89:1.[23, 24] Although the study by Breslow et al(1993) showed a younger age at presentation for males and called for more laboratory studies to explain the differences between males and females in ages-at-onset [3], in this study we could not statistically prove an association of age at presentation and gender.

As the pathogenesis of Wilms' tumor relies mainly on genetics, its' clear ethnic variation is understandable. A lot of work has been done on the incidence in different ethnic groups in the literature. U.S. blacks and Africans from Ibadan Nigeria had the highest incidence. [6] Sudan is an ethnic melting pot with diversity of races greater than most countries. The percentage of Wilms' tumor in this study shows a marked increase in western tribes in Sudan. Such variation as does exist is more closely associated with race than geography. [3] These patients present with a more aggressive disease and lung metastasis ($P < 0.024$). On the other hand, patients from Southern tribes of the Sudan presented with inoperable masses ($P < 0.016$), yet no metastasis.

Ninety-eight percent of this study's patients presented with abdominal mass, in contrast to the United Kingdom Children's Cancer Study Group (UKCCSG) who reported this rate to be 74% [25], and in Johannesburg South Africa where they reported it to be 76% [26]. Our figure is closer to other developing countries, e.g. Alexandria 86.6% [21], and Iran 90.9%. [22] Early detection in developed countries could be explained by the availability of health services and increased awareness of the society. However, our percentage of patients presenting with fever and weight loss are more than triple the figures from these countries. This could be due to similar symptoms manifested by other

endemic infectious diseases in Sudan that might lead patients' families and rural health workers to relate the symptoms to these diseases.

Table12: Country-Wise data of Clinical presentation and histology of Wilms tumor cases.

Signs/symptoms	Sudan (Present study)	Kenya[27]	South Africa[28]	Egypt[29]	Iran[30]	Nigeria [31]	Jordan[32]
Abdominal mass	50%	97.7%	77%	65%	90.9%	-	-
Abdominal pain	12%	-	25.5%	3.5%	10.9%	32%	-
Hematuria	5%	6.8%	9.6%	5%	14.5%	16%	-
Weight loss	22%	34.5%	20.7%	1.5%	1.8%	56%	-
Fever	18%	16.5%	-	-	5.5%	-	-
Vomiting	-	10.5%	-	3%	-	-	-
Epistaxis	2%	-	-	-	-	-	-
Others	5%	33.1%	13%	19%	1.8%	-	-
Histology:Favourable	92.15%	-	87.27%	32.6%	-	96.7%	86.9%
Histology:Unfavourable	7.85%	-	12.8%	65.2%	-	3.3%	15.1%

Table13:Presentation of Wilms tumor as reported in different studies in other countries[5,33,29, 32,28,27]

Country	M:F	Median Age at diagnosis(Y)	Stage at diagnosis					Unknown
			I	II	III	IV	V	
Sudan (Present study)	1.5:1	3.4	1.96%	33.33%	43.14%	21.57%	-	-
Sudan	0.9:1	4.1	3%	19%	68%	11%	-	-
Iran	1:1	3.8	23%	35%	32%	5%	4%	-
Egypt	1:1	3.8	23.3%	35.4%	32.4%	5.1%	3.8%	-
Jordan	1.17:1	3.3	27.9%	34.4%	16.4%	11.5%	9.8%	-
SouthAfrica	0.8:1	3.8	37%	18%	24%	21%	-	-

SouthAfrica	2:3	3.25	57%	33%	60%	38%	-	-
Kenya	1.14:1	-	3.2%	42.4%	36%	16.8%	1.6%	-
Malawi	1:1	3.5	24%	39%	37%	-	-	-
United kingdom	1.1:1	2.8	60%	19%	20%	-	-	1%
Germany	1.1:1	3.4	58%	11%	8%	20%	3%	-

In our study, the majority of patients presented in the stage II and III, and it is similar to another study reported in Sudan.[5] (Table 12& 13). Earlier presentations has been reported from developed countries(table 20).Patients with epistaxis presented early, and those with hematuria had smaller tumors and stage II disease. Von Willebrand factor(VWF) testing was not done in our case who presented with epistaxis. Early presentation by patients with epistaxis can be explained by the fact that bleeding is a more alarming symptom. The cause is most likely to be acquired Von Willebrand's syndrome (AVWS) type III according to a French study on the causes of AVWS. [34]

Patients with aniridia, anomalies of the male genitalia, and the Beckwith-Weidemann syndrome tend to have substantially younger ages at diagnosis.[3] An association between age at presentation and congenital anomalies was not statistically proven in our study. However, the absence of lymph node metastasis was statistically significant in those patients ($P<0.045$) implying a better outcome. That could be due to a milder disease form in those patients, or more logically, their families sought medical help sooner than those patients who seemed normal to their families.

Lung and liver metastasis were the most common sites. The site of metastasis correlated with the duration of symptoms ($P<0.010$). Patients with liver and bone metastasis took a longer time to seek medical help. Breslow et al (1986) for the NWTs, found that distant metastasis at presentation correlated to capsular invasion, as did the author ($P<0.027$). In that study, they found that all the indicators of regional spread of the disease within the abdomen were strongly associated with the presence of metastases. Patients with overt disease in the abdominal cavity or with microscopic tumor in the surgical margin were more than twice as likely to have distant metastases, than were those whose tumor was apparently confined to the kidney. If there was microscopic evidence of lymph node involvement or invasion of the renal vasculature, whether inside the kidney or outside, the finding of concomitant metastasis was increased at least threefold.[35]

The type of histological predominance in triphasic tumors correlated to the size of the mass: mesenchymal predominance in smaller sizes and blastemal predominance in larger tumors. A study by Sidhom et al (2004) found that presence of blastemal predominance had an adverse effect on outcome. In this study we were unable to find statistical relation of blastemal predominance to other factors of poor outcome.[36]

Analyses of the histology of Wilms' tumors occurring in patients with sporadic tumors with WT1 mutation have shown that stromal differentiation, particularly along muscle lines, tends to predominate.[37] Pritchard-Jones suggests that the normal role of WT1 may be to suppress muscle differentiation in the primitive metanephric mesenchymal cells.[38] In our study the presence of muscle in the stroma (25.5%) was found to correlate with less advanced stages of the disease ($P < 0.016$), and with the absence of weight loss in the presenting symptoms ($P < 0.019$). This is in concordance with the concept that the presence of relatively mature skeletal muscle "fetal rhabdomyomatous nephroblastoma" carries a favorable prognosis and should not be confused with rhabdomyosarcoma that has the opposite prognosis.[39]

On the other hand, presence of adipose tissue correlated to the tumor not being confined to the kidney ($P < 0.008$). This finding will need support by other larger studies to validate this relation.

Anaplasia "threefold nuclear enlargement, hyperchromasia, and atypical mitotic figures" [19] is the most valued prognostic parameter in all the literature. Anaplastic tumors were detected in 7.8% of our study group. This was less than the NWTS 12%, [40] but is comparable to that found in Johannesburg. [26] In this study, anaplasia had statistically significant relationship with older age groups ($P < 0.030$), tumor not confined to the kidney ($P < 0.050$) and presence of capsular invasion ($P < 0.021$). Although all anaplastic tumors were stage III, in this study, no statistical significance was proved. As D'Angio et al. stated in NWTS 3, the outlook has been poor for the children afflicted with the anaplastic form of Wilms' tumor. We can confer from these findings the correlation of anaplasia with poor outcome. However, its relationship with unresponsiveness to therapy, or lack of relations to aggressiveness will need larger studies with monitoring of response to therapy. [41, 42]

The NWTS revealed that lymph nodes or distant metastasis were the most important poor prognostic indicators.[43] Invasion of the renal capsule, intrarenal vessels, or renal sinus and lack of a perirenal inflammatory reaction were designated as "microsub-staging" factors and are related to negligible relapse rates.[44] In this study, 5 patients had lymph node metastases. It was found to be closely related to capsular invasion ($P < 0.047$). Capsular invasion was detected in 11 patients. Its absence was mostly seen in patients who presented after a short duration of symptoms ($P < 0.001$). Three out of the 4 patients with inoperable tumors showed no necrosis in their histology ($P < 0.002$), and they have not received any preoperative chemotherapy. Boccob et al. demonstrated that post chemotherapy necrotic tumors have excellent outcome.[45] However, the cultural and socioeconomic status of our patients and lack of guidance delay their diagnosis and worsen their outcome.

One case of the rare teratoid Wilms' tumor was found in this series and requires special mention. As stated by Meyers et al. of a review of all the teratoid Wilms' tumors reported

online to that date, teratoid Wilms' tumors appear to present with a high stage, increased incidence of bilaterality and have a high mortality rate.[46]

Conclusion:

The mean age at presentation of Sudanese patients is in concordance with international studies; but to the contrary, it had no statistical correlation to gender. On the other hand, a male-to-female ratio shows a slight male preponderance, disagreeing with the findings of NWTs.

The disease was more prevalent in the west of Sudan, where they had aggressive disease presenting with lung and liver metastases. Abdominal mass was the major presenting symptom, followed by fever and weight loss, which was more than other reported in the literature.. Capsular invasion “indicator of regional spread of the disease” was strongly associated with the presence of metastases.

Mesenchymal presence predominated in smaller tumor and blastemal component was predominant in larger tumors. There was a relationship between the histology of the tumor and clinical symptoms. A milder course of the disease was also related to tumors with rhabdomyomatous elements in the stroma. Anaplasia was related to older age at presentation, locally infiltrative tumors, presence of capsular invasion, and advanced clinical stage.

Conflicts of Interest: The authors declare that there are no conflicts of interest.

Acknowledgements:

This work would not have been completed without the valuable help from Soba teaching hospital staff: Hussain M. Obeid in pediatric surgery archive, Mustafa Mousa in the main archive, Samah Haroun and Mutasim Khamees in the Lab. Miss Afaf at NHL was of great help obtaining archived slides. Our thanks are also extended to Mr. Hassan Ali for his work with the statistics. Dr. A B Salih has revised, read and proofread this work with valuable comments and corrections

References

1. Charles AK, Vujanic GM, Berry PJ, Renal Tumors of Childhood, *Histopathology* 32, 293-309 (1998).
2. Murphy AJ, Axt JR, Caestecker CD, Pierce J, Correa H, Seeley EH et al. Molecular characterization of Wilms' tumor from a resource-constrained region of sub-Saharan Africa. *Int J Cancer*; 131(6), E983-994.2012
3. Breslow N, Olshon A, Beckwith JB, et al Epidemiology of Wilms' Tumor. *Med PediatrOncol* 21: 172-81;1993.
4. Stiller CA, Parkin DM: International variations in the incidence of childhood renal tumours. *Br J Cancer* 1990; 62: 1026–1030.

5. Cunningham ME, Klug TD, Nuchtern JG, Chintagumpala MM, Venkatramani R, Lubega J, Naik-Mathuria BJ. Global Disparities in Wilms Tumor. *J Surg Res.* 2020 Mar 247:34-51
6. Norman Breslow, Andrew Olshan, J. Bruce Beckwith, Jami Moksness, Polly Feigl, Daniel Green. Ethnic Variation in the Incidence, Diagnosis, Prognosis, and Follow-up of Children with Wilms' Tumor. *Journal of the National Cancer Institute, Vol. 86, No. 1, January 5, 1994*
7. Dome, Jeffrey S; Coppes, Max J. Recent advances in Wilms tumor genetics. *Current Opinion in Pediatrics: February 2002 - Volume 14 - Issue 1 - pp 5-11 Hematology and oncology*
8. Daniel M. Green, Giulio J. D'Angio, J. Bruce Beckwith, Norman E. Breslow, Paul E. Grundy, Michael L. Ritchey, Patrick R. M. Thomas, Wilms' Tumor CA: A Cancer Journal for Clinicians, Volume 46, Issue 1, pages 46–63, January/February 1996
9. Kumar V, Abbas AK, Fausto N. *Robins and Cotran Pathologic Basis of Disease 7th edition, chapter 10, ©2005 Elsevier Inc.*
10. [http://eMedicine Specialties > Urology > Cancer, Wilms Tumor and Neuroblastoma](#)
Wilms Tumor Author: Marc Cendron, Boston Coauthor: Pablo Gomez III.
11. William L. Gerald, The Molecular Genetics of Wilms Tumor: A Paradigm of Heterogeneity in Tumor Development, *Cancer Investigation.* 12(3), 350-359 (1994).
12. Wendy Bruening, Elaine Winnett, Jerry Pelletier, Wilms' Tumor: A Paradigm for Insights into Development and Cancer, *Cancer Investigation,* 13(4), 431-443 (1995).
13. Drash A, Sherman F, Hartmann WH, et al: A syndrome of pseudohermaphroditism, Wilms' tumor, hypertension, and degenerative renal disease. *J Pediatr* 76:585-593, 1970.
14. Pettenati MJ, Haines JL, Higgins RR, et al: Wiedemann-Beckwith syndrome: Presentation of clinical and cytogenetic data on 22 new cases and review of the literature. *Hum Genet* 74:143-154, 1986.
15. Hemant B. Tongaonkar, Sajid S. Qureshi, Purna A. Kurkure, Mary-Ann A. Muckaden, Brijesh Arora, and Thyavihalli B. Yuvaraja. Wilms' tumor: An update, *Indian J Urol.* 2007 Oct–Dec; 23(4): 458–466.
16. Pritchard-Jones K. Controversies and advances in the management of Wilms' tumor. *Arch Dis Child* 2002;87:241–244.
17. Ritchey ML, Shamberger RC, Hamilton T, Haase G, Argani P, Peterson S. Fate of bilateral renal lesions missed on preoperative imaging: A report from the National Wilms Tumor Study Group. *J Urol.* 2005;174:1519–21.
18. Breslow N, Sharples K, Beckwith JB, Takashima J, Kelalis PP, Green DM, et al. Prognostic factors in non-metastatic, favorable histology Wilms' tumor: Results of the Third National Wilms' Tumor Study. *Cancer.* 1991;68:2345–53.
19. Beckwith JB, Palmer NF: Histopathology and prognosis of Wilms tumor. Results from the first National Wilms Tumor Study. *Cancer* 41: 1937- 1948, 1978.

20. Abuidris DO, Ahmed ME, Elgaili EM, Arora RS. Childhood cancer in Sudan: 1999-2007 Trop Doct.38(4):208-10;Oct 2008.
21. N. El-Ghamry, A. Omran, H. Kohail, A. Omar, M. El-Ghamry, M. A/Fattah. Clinicopathological Features and Treatment Results of Wilms' Tumor: A Retrospective Study of 127 Patients in Alexandria, Egypt.Proc Am SocClinOncol 19: 2000
22. Mir-MahmoodSeyed-Ahadi, Ahmad Khaleghnejad-Tabari,AlirezaMirshemirani, NaserSadeghian , OmidAmonollahi MD. Wilms' Tumor: A 10 Year Retrospective Study. Arch Iranian Med 2007; 10 (1): 65 – 69
23. Guido Pastore, Modesto Carli, Jean Lemerle, Marie F. Tournade, Paul A. Voute, Annie Rey, J. Marion V. Burgers, Jean M. Zucker, Dietrich Burger, Jan De Kraker, Jan F. M. Delemarre. Epidemiological features of Wilms' tumor: Results of studies by the international society of paediatric oncology (SIOP). Medical and Pediatric Oncology, vol 16 Is 1:7-11, 1988.
24. Norman Breslow, J. Bruce Beck with, Marcia Ciol, and Katrina Sharples. Age Distribution of Wilms' Tumor: Report from the National Wilms' Tumor Study1 Cancer Research 48. 1653-1657. March 15. 1988]
25. Pritchard U, Imeson J, Barnes J, Cotterill S, Gough D, Marsden HB, et al. Results of the United Kingdom Children's Cancer Study Group first Wilms' tumor study (UKW1). J ClinOncol. 1995; 13: 124 – 133
26. T. Rogers¹, D. M. Bowley¹, J. Poole², P. Swanepoel³, J.Wainwright², P. Beale¹, G. Pitcher¹Experience and Outcomes of Nephroblastomain Johannesburg, 1998–2003 Eur J PediatrSurg 2007; 17: 41–44
27. Axt J, Abdallah F, Axt M, et al. Wilms tumor survival in Kenya. J Pediatr Surg. 2013;48(6):1254–1262. doi:10.1016/j.jpedsurg.2013.03.021
28. Davidson A, Hartley P, Desai F, Daubenton J, Rode H, Millar A. Wilms tumour experience in a South African centre. Pediatr Blood Cancer. 2006 Apr;46(4):465-71
29. Faranoush M, Bahoush GR, MehrvarA,Wilm's Tumor: Epidemiology and Survival. Research Journal of Biological Sciences 4 (1): 86-89, 2009
30. Seyed-Ahadi MM¹, Khaleghnejad-Tabari A, Mirshemirani A, Sadeghian N, Amonollahi O. Wilms' tumor: a 10 year retrospective study. Arch Iran Med. 2007 Jan;10(1):65-9
31. Atanda AT¹, Anyanwu LJ, Atanda OJ, Mohammad AM, Abdullahi LB, Farinyaro AU. Wilms' tumour: Determinants of prognosis in an African setting. Afr J Paediatr Surg. 2015 Jul-Sep;12(3):171-6. doi: 10.4103/0189-6725.170185
32. Mustafa M, M., Hamoury M, M., Hassan R, S. (2014). Wilms' Tumor in Children : A Single Institution 10-Year Experience. The Egyptian Journal of Hospital Medicine, 55(1), 159-164. doi: DOI: 10.12816/0004501
33. Abuidris DO¹, Elimam ME, Nugud FM, Elgaili EM, Ahmed ME, Arora RS. Wilms tumour in Sudan; Pediatr Blood Cancer. 2008 Jun;50(6):1135-7. doi: 10.1002/pbc.21547

34. Michiels Jan Jacques, Budde Ulrich, Van Der Planken Marc, Van Vliet Huub H. D. M., Schroyens Wilfried, Berneman Zwi. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management, Baillière's best practice & research. Clinical haematology ISSN 1521-6926, 2001, vol. 14, no2, pp. 401-436.
35. Breslow Norman E., Gary Churchill, Barbara Nesmith, Patrick R. M. Thomas, J. Bruce Beckwith, MD, H. Biemann Othersen, MD, And Glullo J. D'angio, MD. For The National Wilms' Tumor Study Group' Clinicopathologic Features and Prognosis for Wilms' Tumor Patients With Metastases at Diagnosis. Cancer 58:2501-2511, 1986.
36. I. Sidhom, H. Hussien, M. Kotb, G. Anwer, S. Aboul Naga, M. Amin, E. Ebied, H. Ahmed. Multidisciplinary Approach to Wilms' Tumor: 10 Years' Experience of NCI, Egypt. Journal of Clinical Oncology, Vol 22, No 14S 2004.
37. Schumacher V, Schneider S, Figge A, Wildhardt G, Harms D, Schmidt D, et al. Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology. Proc Natl Acad Sci U S A 1997;94:3972-7.)
38. Pritchard-Jones, K. Malignant Origin of the Stromal Component of Wilms' Tumor, Journal of the National Cancer Institute, Vol. 89, No. 15, August 6, 1997.
39. Fletcher, Christopher D.M. Diagnostic Histopathology of Tumors. 2nd Revised edition, 12-Sep-2000. Elsevier Saunders
40. Belasco J., D'angio G. J., Wilms' Tumor Cancer Journal for Clinicians Vol. 31, No. 5 September -October 1981.
41. D'Angio GJ, Breslow N, Beckwith JB, Evans A, Baum H, deLorimier A, et al. Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study. Cancer. 1989; 64: 349 – 360.
42. Beckwith J. Bruce, Zuppan Craig E., Nancy G. Browning, Jami Moksness, Breslow Norman E. Histological analysis of aggressiveness and responsiveness in Wilms' tumor Medical and Pediatric Oncology; Volume 27, Issue 5, pages 422–428, November 1996.
43. Breslow NE, Palmer NF, Hill LR, et al: Wilms' tumor: prognostic factors for patients without metastases at diagnosis: results of the National Wilms' Tumor Study. Cancer 41:1577-1589, 1978.
44. Weeks DA, Weeks DA, Beckwith JB, Luckey DW: Relapse associated variables in stage I favorable histology Wilms tumor. A report from the National Wilms Tumor Study. Cancer 60:1204-1212, 1987.
45. Boccon-Gibod L, Rey A, Sandstedt B, et al. Complete necrosis induced by preoperative chemotherapy in Wilms tumor as an indicator of low risk: report of the international society of pediatric oncology (SIOP) nephroblastoma trial and study 9. Medical Pediatric Oncology 2000; 34: 183–90.

46. Myers JB, Dall'Era J, Odom LF, McGavran L, Lovell MA, Furness P 3rd. Teratoid Wilms' tumor, an important variant of nephroblastoma. *J Pediatr Urol.* 2007 Aug;3(4):282-6.